1 day Ago By ABMN Staff
Opus Genetics ( NASDAQ:IRD – Free Report ) had its target price trimmed by Jones Trading from $9.00 to $8.00 in a research report sent to investors on Tuesday morning, Benzinga reports.
The brokerage currently has a buy rating on the stock. Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Opus Genetics in a research note on Tuesday.
Get Our Latest Analysis on Opus Genetics Opus Genetics Stock Performance Opus Genetics ( NASDAQ:IRD – Get Free Report ) last issued its quarterly earnings results on Monday, March 31st. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.
34) by ($0.93). Opus Genetics had a negative return on equity of 63.
65% and a negative net margin of 324.45%. The company had revenue of $3.
40 million during the quarter, compared to the consensus estimate of $11.10 million. On average, research analysts anticipate that Opus Genetics will post -1.
22 earnings per share for the current year. Opus Genetics Company Profile ( Get Free Report ) Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Further Reading Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter ..
_8.jpg?itok=wp-xhXRB)
